Image de couverture de livre

Letter: Addressing opioid exposure and associated harms in patients with IBD

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Christian P. Selinger, Samantha Baillie, Richard Pollok
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
par: Samantha Baillie, et autres
Publié: (2025)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
par: Richard Pollok
Publié: (2025)

Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population‐Based Cohort Study
par: Samantha Baillie, et autres
Publié: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
par: Isabel Carbery, et autres
Publié: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
par: Guofu Mao, et autres
Publié: (2026)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
par: Xueneng Yang, et autres
Publié: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
par: Alice S. Day, et autres
Publié: (2025)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
par: Xinli Chen, et autres
Publié: (2024)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
par: Luisa Bertin, et autres
Publié: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
par: Chachrit Khunsriraksakul, et autres
Publié: (2025)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
par: Arta Aliu, et autres
Publié: (2024)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
par: Luisa Bertin, et autres
Publié: (2026)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
par: Jakob B. Seidelin
Publié: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
par: Maria Ling Lundström, et autres
Publié: (2024)

Editorial: Getting to the Heart of the Matter in IBD
par: Ashwin N. Ananthakrishnan
Publié: (2025)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
par: Rui Zhang, et autres
Publié: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
par: Min Wu, et autres
Publié: (2024)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
par: Shamim Joudaki, et autres
Publié: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
par: Ramin Ebrahimi, et autres
Publié: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
par: Daniele Noviello, et autres
Publié: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations
par: Zhen Deng, et autres
Publié: (2025)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
par: Darcy Quinn Holt, et autres
Publié: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
par: James L. Alexander, et autres
Publié: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
par: Parul Tandon, et autres
Publié: (2025)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
par: Andrew W. Nguyen, et autres
Publié: (2026)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
par: Alberto Ferrarese, et autres
Publié: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
par: Shupeng Zhao, et autres
Publié: (2025)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
par: Changhu Sun, et autres
Publié: (2025)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
par: Mustafa Mohamedrashed, et autres
Publié: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
par: Amanda Ricciuto, et autres
Publié: (2024)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
par: Giovanni Cammarota, et autres
Publié: (2024)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
par: Adam S. Faye, et autres
Publié: (2025)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
par: Keith Bodger
Publié: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
par: Shabari Shenoy, et autres
Publié: (2025)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
par: Yaomin Wang, et autres
Publié: (2024)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
par: Merle Claßen, et autres
Publié: (2024)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
par: Fahim Ebrahimi, et autres
Publié: (2024)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
par: Katherine L. Stone, et autres
Publié: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
par: Olga M. Nardone, et autres
Publié: (2025)